Zura Bio Limited

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

A lot of biopharmaceutical companies have changed their strategies during the past year or two with investors less receptive to stock offerings in 2022 and 2023 than they were in the two prior years,

The two biggest biopharmaceutical initial public offerings in the US so far in 2023 occurred during the first week of May, although the largest of the two was a consumer health care spinout from a dru

With biotechnology stock valuations down for more than two years since peaking in February 2021, the industry has gotten somewhat used to volatility, but recent fluctuations paint a clear picture of h